The estimated Net Worth of Shankar Musunuri is at least $5.17 Million dollars as of 17 January 2023. Dr Musunuri owns over 100,000 units of Ocugen Inc stock worth over $2,863,379 and over the last 5 years he sold OCGN stock worth over $1,524,900. In addition, he makes $780,673 as Co-Founder and Chairman & CEO at Ocugen Inc.
Sign up
Dr D OCGN stock SEC Form 4 insiders trading
Dr has made over 16 trades of the Ocugen Inc stock since 2019, according to the Form 4 filled with the SEC. Most recently he exercised 100,000 units of OCGN stock worth $51,000 on 17 January 2023.
The largest trade he's ever made was buying 406,000 units of Ocugen Inc stock on 11 December 2019 worth over $158,340. On average, Dr trades about 90,016 units every 49 days since 2019. As of 17 January 2023 he still owns at least 2,327,950 units of Ocugen Inc stock.
You can see the complete history of Dr Musunuri stock trades at the bottom of the page.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Dr. Shankar Musunuri M.B.A., MBA, Ph.D. biography
Dr. Shankar Musunuri M.B.A., MBA, Ph.D. is the Co-Founder, Chairman & CEO at Ocugen Inc.
What is the salary of Dr D?
As the Co-Founder and Chairman & CEO of Ocugen Inc, the total compensation of Dr D at Ocugen Inc is $780,673. There are no executives at Ocugen Inc getting paid more.
How old is Dr D?
Dr D is 57, he's been the Co-Founder and Chairman & CEO of Ocugen Inc since . There are 7 older and 9 younger executives at Ocugen Inc. The oldest executive at Ocugen Inc is Prabhavathi Fernandes, 71, who is the Independent Director.
What's Dr D's mailing address?
Shankar's mailing address filed with the SEC is C/O OCUGEN, INC., 11 GREAT VALLEY PARKWAY, MALVERN, PA, 19355.
Insiders trading at Ocugen Inc
Over the last 5 years, insiders at Ocugen Inc have traded over $18,069,176 worth of Ocugen Inc stock and bought 1,511,356 units worth $684,830 . The most active insiders traders include Shankar Musunuri, Junge Zhang, and Uday Kompella. On average, Ocugen Inc executives and independent directors trade stock every 21 days with the average trade being worth of $96,347. The most recent stock trade was executed by Junge Zhang on 14 June 2023, trading 200,278 units of OCGN stock currently worth $100,139.
What does Ocugen Inc do?
ocugen, inc., is a rapidly growing ophthalmology company developing a rich clinical pipeline of innovative therapies that address rare and underserved ocular disorders. the company’s lead programs in ocular graft versus host disease (ocu300) and chronic dry eye disease (ocu310) are expected to enter pivotal clinical trials in 2018. ocu300 received the first and only orphan drug designation for ocular graft versus host disease, providing certain regulatory and economic benefits. ocugen is also developing novel biologic therapies for retinitis pigmentosa (ocu100) and wet amd (ocu200), as well as a groundbreaking modifier gene therapy platform with potential to address a broad spectrum of inherited retinal disorders (ocu400). for more information, please visit www.ocugen.com.
What does Ocugen Inc's logo look like?
Complete history of Dr Musunuri stock trades at Ocugen Inc
Ocugen Inc executives and stock owners
Ocugen Inc executives and other stock owners filed with the SEC include:
-
Dr. Shankar Musunuri M.B.A., MBA, Ph.D.,
Co-Founder, Chairman & CEO -
Shankar Musunuri,
Chairman of the Board, Chief Executive Officer -
Sanjay S. Subramanian M.B.A.,
Chief Accounting Officer, CFO, Treasurer, Head of Corp. Devel. & Corp. Sec. -
Rasappa Arumugham,
Chief Scientific Officer -
Dr. Uday B. Kompella Ph.D.,
Co-founder & Independent Director -
Junge Zhang,
Independent Director -
Suha Taspolatoglu,
Independent Director -
Manish Potti,
Independent Director -
Ramesh Kumar,
Independent Director -
Uday Kompella,
Independent Director -
Prabhavathi Fernandes,
Independent Director -
Kirsten Castillo,
Independent Director -
Kelly Beck,
Vice President, Investor Relations and Administration and Corporate Secretary -
Vijay Tammara,
Senior Vice President - Regulatory and Quality -
Sanjay Subramanian,
Chief Financial Officer, Chief Accounting Officer, Treasurer -
Michael Shine,
Sr. VP of Commercial -
J. P. Gabriel,
Sr. VP of Manufacturing & Supply Chain -
Dr. Bruce D. Forrest B.S., M.B.A., M.D.,
Acting Chief Medical Officer & Vaccine Scientific Advisory Board Member -
Dr. Arun Upadhyay Ph.D.,
Head of Research, Devel. & Discovery -
Dr. Vijay Tammara,
Sr. VP of Regulatory & Quality -
Zara Gaudioso,
Head of HR -
Ken Inchausti,
Head of Investor Relations & Communications -
Jessica Crespo,
CAO/SVP, Finance -
Daniel Jorgensen,
Chief Medical Officer -
Frank Leo,
Director -
Marna C Whittington,
Director -
Huma Qamar,
Chief Medical Officer -
Arun Upadhyay,
See Remarks